Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.59 |
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ASPH | Q12797 | 2/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.47 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203409 | 0.87 | FYN (0.56) | FYNPIM1CLK1NTRK1NPC1 | |
| SCHEMBL2906861 | 0.86 | FYN (0.51) | FYNPIM1CLK1NTRK1VNN1 | |
| SCHEMBL2902453 | 0.86 | PIM1 (0.61) | FYNPIM1MKNK1NTRK1 | |
| SCHEMBL2902438 | 0.86 | FYN (0.57) | FYNNTRK1 | |
| SCHEMBL1202088 | 0.85 | FYN (0.63) | FYNPIM1KDM4EMKNK1NTRK1 | |
| SCHEMBL1203239 | 0.84 | FYN (0.51) | FYNPIM1CLK1KDM4ENTRK1 | |
| SCHEMBL2943172 | 0.84 | FYN (0.69) | FYNPIM1MKNK1NTRK1 | |
| SCHEMBL1203735 | 0.84 | FYN (0.52) | FYNPIM1CLK1NTRK1 | |
| SCHEMBL1203328 | 0.84 | FYN (0.55) | FYNPIM1CLK1NTRK1 | |
| SCHEMBL1203065 | 0.83 | PPARA (0.54) | FYNPIM1NTRK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 403/4885PIM1 1/4885CLK1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.